MarginsXMarginsX
Home › Markets › Health Care › EOCN

Eocene Ltd. (EOCN)

EOCN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.53
+5.86% on the day
Market cap
$2.6M
Nano cap
Revenue · 2020
$0
Prior year not contiguous
Net income · 2020
-$28.8M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1595353/000110465921038205/0001104659-21-038205-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerEOCN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2014
SEC CIK0001595353
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2020

LineValue
Revenue$0
Net income-$28.8M
Operating income-$30.2M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$6.9M
Total assets$52.4M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
7.6 months
$4.0M cash at December 31, 2025
Share count, 1 year
+297.8%
2024-12-31 to 2025-12-31 · +4600.4% over 3 years
Going-concern doubt
No
20-F filed March 31, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below: our ability to pursue, evaluate and complete any strategic alternative that yields value for our shareholders; the development and approval of the use of Aramchol or any other product candidate for indicat"
20-F 2026-03-31
Cash and burn$4.0M cash; operating cash flow -$1.6M a quarter.Report 2025-12-31
Shares outstanding822,674 (2025-12-31); 1,654,428 a year earlier; 25,203,396 three years earlier. 3y figure adjusted for splits (1-for-180 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years2; latest 1-for-8 on 2026-08-19Source 2026-08-19
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBrightman Almagor Zohar & Co., Tel Aviv, IsraelPCAOB Form AP 2026-05-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$10.3M-$6.3M$4.0MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2024
2024-12-31
Not filed-$7.5M-$5.9M$4.7MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2023
2023-12-31
Not filed-$6.9M-$6.1M$2.9MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2022
2022-12-31
Not filed-$17.9M-$18.5M$2.0MNo debt tagsNeeds four quarters20-F 2025-04-02
FY 2021
2021-12-31
Not filed-$32.5M-$32.9M$2.9MNo debt tagsNeeds four quarters20-F 2024-04-04
FY 2020
2020-12-31
$0-$28.8M-$26.3M$6.9MNo debt tags$020-F 2021-03-18
FY 2019
2019-12-31
$0-$20.5M-$14.9M$15.9MNo debt tags$020-F 2021-03-18
FY 2018
2018-12-31
$2.0M-$9.9M-$9.0M$24.2MNo debt tags$2.0M20-F 2021-03-18

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-09-02
Latest annual report20-F2026-03-31
Latest quarterly / interim6-K2026-11-16

Source: SEC EDGAR submissions feed, 383 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.5%
1 month-21.6%
3 months-41.6%
Year to date-58.7%
1 year-71.0%
From 52-week high-74.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
REVBRevelation Biosciences Inc.$3.82-10.43%$2.6M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
GNPXGenprex Inc.$1.90-8.65%$2.5M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier